State Court Activity
Active litigation in California state courts including San Mateo County (Hardiman personal injury) and San Francisco (Harris estate wrongful death, case CGC-24-621022)
Pharmaceutical · drug-safety monitoring around Oxbryta and possible litigation tied to adverse events or market actions
Defendant
Pfizer Inc.
MDL / Track
See litigation status
N.D. Cal.
Judge
Judge Trina L. Thompson
Plaintiffs
ACTIVE
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Pfizer voluntarily withdrew Oxbryta (voxelotor) globally in September 2024 after post-marketing studies showed increased vaso-occlusive crises and fatal events. Federal product liability and wrongful-death suits are proceeding against Pfizer and Global Blood Therapeutics, with trials scheduled for 2027 in cases including Allen v. Global Blood Therapeutics, Inc. (trial June 7, 2027) and Ford v. Global Blood Therapeutics, Inc. (trial September 13, 2027). Plaintiffs allege defendants promoted the drug as safe while failing to disclose real-world evidence of VOCs, stroke, and death.
Causation Theory
Voxelotor's mechanism—binding the α-globin subunit to stabilize hemoglobin S in the oxygenated state—may paradoxically reduce oxygen delivery to tissues. The HOPE Kids 2 trial (post-marketing commitment) showed 8 fatal treatment-emergent adverse events in the voxelotor arm versus 2 in placebo. Preliminary data from the RETRO and PROSPECT registries suggested increased acute pain crisis after voxelotor initiation. The FDA's September 26, 2024 Drug Safety Communication and EMA's independent review confirmed the withdrawal based on this risk-benefit imbalance.
Litigation status
Federal cases coordinated in N.D. Cal. under Judge Trina L. Thompson with three confirmed settlements reached through court-ordered mediation by retired Judge Philip S. Gutierrez. First bellwether trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). No MDL established; litigation proceeding through informal coordination with active settlement momentum.
State Court Activity
Active litigation in California state courts including San Mateo County (Hardiman personal injury) and San Francisco (Harris estate wrongful death, case CGC-24-621022)
Geographic exposure
Approximately 100,000 sickle cell disease patients in U.S., 90% non-Hispanic Black or African American; pediatric approval expanded 2021 to ages 4-11. FDA approval November 2019 to global withdrawal September 2024 creates exposure window.
Plaintiff Tirrell Allen (resident) filed first federal suit November 2024 alleging stroke and severe vaso-occlusive crises after August 2024 Oxbryta initiation; Allen v. Pfizer selected as first federal trial. Northern District of Illinois venue under consideration for MDL consolidation per April 2025 filings.
At least six state court suits filed as of April 2025, including wrongful death action April 15, 2025 in Bay Area hospital networks and April 16, 2025 Oakland suit naming Sutter-affiliated hospitals. Northern District of California (Judge Trina L. Thompson) currently houses two federal complaints under single-judge management.
Venue of first wrongful death case filed; District of South Carolina under consideration for MDL consolidation per plaintiff bar April 2025 draft motion to JPML.
Two suits on record as of early 2025 per litigation tracking data.
236 children aged 2-15 with high stroke risk enrolled across several countries — 8 deaths in Oxbryta arm vs. 2 in placebo arm reported 2024, prompting EMA CHMP immediate suspension of EU marketing authorization September 2024.
88 patients aged 12+ with known Oxbryta exposure — 8 deaths reported prompting FDA safety communication and Pfizer global withdrawal September 2024.
150 patients enrolled as of September 2023 data cutoff; 89.3% Black or African American, mean age 31.5 years, 70% HbSS genotype. Real-world exposure cohort with 47.5 mean weeks duration.
Key defendants
Pfizer Inc.
Role: Manufacturer
Aggressive preemption defense in personal injury and consumer class actions. Motion to dismiss pending in Allen (3:24-cv-07786-TLT) and Jolly (3:24-cv-09345-TLT), both set for hearing July 8, 2025 before Judge Trina L. Thompson. Argues FDA labeling authority bars state law claims; no 'newly acquired information' for CBE label change. Trial date set for June 7, 2027 in lead personal injury case.
Global Blood Therapeutics, Inc.
Role: Manufacturer
Co-defendant with Pfizer in all pending actions. Acquired by Pfizer in 2022; original developer of Oxbryta. Joint defense posture on preemption and standing. No indemnity disputes visible in case management statements.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Pfizer Inc. | Manufacturer | Aggressive preemption defense in personal injury and consumer class actions. Motion to dismiss pending in Allen (3:24-cv-07786-TLT) and Jolly (3:24-cv-09345-TLT), both set for hearing July 8, 2025 before Judge Trina L. Thompson. Argues FDA labeling authority bars state law claims; no 'newly acquired information' for CBE label change. Trial date set for June 7, 2027 in lead personal injury case. |
| Global Blood Therapeutics, Inc. | Manufacturer | Co-defendant with Pfizer in all pending actions. Acquired by Pfizer in 2022; original developer of Oxbryta. Joint defense posture on preemption and standing. No indemnity disputes visible in case management statements. |
Timeline
FDA Grants Accelerated Approval
FDA approves Oxbryta (voxelotor) for sickle cell disease in patients aged 12 and older based on HOPE trial surrogate endpoint. Drug receives fast track and orphan drug designations.
FDA Expands Approval to Ages 4-11
FDA expands Oxbryta approval to children aged 4-11 years based on HOPE-KIDS 1 phase 2a study data, including new 300mg dispersible tablet formulation.
Pfizer Announces Global Voluntary Withdrawal
Pfizer voluntarily withdraws all lots of Oxbryta from global markets and discontinues all clinical trials. Decision based on post-marketing data showing increased vaso-occlusive crises and deaths.
FDA Issues Safety Alert
FDA issues public safety alert confirming withdrawal, advising physicians to stop prescribing and patients to discontinue use. Alert cites imbalance in vaso-occlusive crises and fatal events in post-marketing trials and real-world studies.
First Oxbryta Lawsuit Filed
First product liability lawsuit filed against Pfizer and Global Blood Therapeutics following global withdrawal.
N.D. Cal. Orders Federal Case Coordination
U.S. District Court for the Northern District of California issues order coordinating three federal actions—Frazier v. Global Blood Therapeutics, Jolly v. Global Blood Therapeutics, and Allen v. Global Blood Therapeutics—before Judge Trina L. Thompson. No MDL established.
Court-Ordered Mediation Begins
Judge Thompson appoints retired Judge Philip S. Gutierrez to oversee settlement mediation. Formal mediation process begins.
First Individual Settlement Reached
Pfizer settles first individual plaintiff case: Frazier v. Global Blood Therapeutics. Parties file status report confirming out-of-court agreement reached during mediation.
Pfizer Settles Pediatric VOC Case
Pfizer settles lawsuit on behalf of 13-year-old plaintiff Z.C. who suffered severe vaso-occlusive crises, first confirmed pediatric settlement in litigation. Second wrongful death settlement also reached in principle.
First Bellwether Trial Scheduled
Jury trial scheduled in Tirrell Allen v. Pfizer Inc. et al., N.D. Cal. before Judge Trina L. Thompson. Plaintiff alleges serious vaso-occlusive crisis injuries. Fact discovery closes November 6, 2026; expert discovery through February 2027.
Second Bellwether Trial Scheduled
Wrongful death trial scheduled in Diana Ford v. Global Blood Therapeutics, Inc. et al., N.D. Cal. Case involves death of Bruce Ford following stroke after increased vaso-occlusive crises on Oxbryta.
Statute of limitations
No MDL established as of March 2026; federal cases coordinated in N.D. Cal. under Judge Trina L. Thompson. September 26, 2024 FDA alert and Pfizer global withdrawal is the critical discovery date for most plaintiffs. Intake priority: Tennessee (1-year SOL expiring September 2025 for pre-withdrawal injuries).
California
2 years from injury
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause
First trial date set: Allen v. Global Blood Therapeutics, Inc., N.D. Cal., Judge Trina L. Thompson, trial June 7, 2027; Ford v. Global Blood Therapeutics, trial Sept. 13, 2027. Federal cases coordinated May 2025 under single judge in N.D. Cal. No MDL yet. September 2024 withdrawal likely triggers discovery rule for many plaintiffs.
Illinois
2 years from discovery of injury
Rule: 735 ILCS 5/13-202; discovery rule per Witherell v. Weimer, 421 N.E.2d 869 (Ill. 1981)
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its causal connection to defendant's conduct
Active filings reported; Tirrell Allen (Illinois resident) filed November 2024. September 2024 global withdrawal is likely discovery date for most plaintiffs.
⚠Tennessee
1 year from discovery of injury
Rule: Tenn. Code Ann. § 28-3-105; discovery rule per Shadrick v. Coker, 963 S.W.2d 726 (Tenn. 1998)
Discovery: Accrues when injury is discovered or reasonably should have been discovered; narrow construction—mere suspicion insufficient
Shortest SOL in major filing states. September 2024 withdrawal = hard discovery date. Intake must screen for any earlier symptoms that could trigger earlier accrual.
New York
3 years from discovery
Rule: N.Y. C.P.L.R. § 214-c; discovery rule per LaRosa v. Scientific Design Co., 402 N.E.2d 1275 (N.Y. 1980)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause; 10-year repose cap from act/omission per § 214-c(2)
2019 FDA approval to 2024 withdrawal falls within repose period. September 2024 withdrawal is clear discovery trigger.
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule per Neagle v. Nelson, 685 S.W.2d 11 (Tex. 1985)
Discovery: Accrues when plaintiff discovers, or in exercise of reasonable diligence should have discovered, the nature of the injury
Large sickle cell patient population. September 2024 withdrawal is discovery date for most. No MDL means state court filings likely.
Georgia
2 years from discovery
Rule: O.C.G.A. § 9-3-33; discovery rule per Am. Medical Int'l, Inc. v. Giurintano, 596 S.E.2d 604 (Ga. 2004)
Discovery: Accrues when plaintiff discovers, or through reasonable diligence should have discovered, both the injury and its cause; 10-year repose for medical products per § 9-3-71(b)
Significant sickle cell population. 2019 approval to 2024 withdrawal within repose. September 2024 withdrawal = discovery trigger.
North Carolina
3 years from discovery
Rule: N.C. Gen. Stat. § 1-52(16); discovery rule per Sawyer v. Foster, 615 S.E.2d 42 (N.C. 2005)
Discovery: Accrues when plaintiff discovers, or should have discovered through reasonable diligence, the injury and its cause; 10-year repose per § 1-50(a)(5) for products liability
Extended SOL favorable for intake. September 2024 withdrawal is discovery date. Repose period covers 2019-2024 marketing.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| California | 2 years from injury | Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause | First trial date set: Allen v. Global Blood Therapeutics, Inc., N.D. Cal., Judge Trina L. Thompson, trial June 7, 2027; Ford v. Global Blood Therapeutics, trial Sept. 13, 2027. Federal cases coordinated May 2025 under single judge in N.D. Cal. No MDL yet. September 2024 withdrawal likely triggers discovery rule for many plaintiffs. |
| Illinois | 2 years from discovery of injury | 735 ILCS 5/13-202; discovery rule per Witherell v. Weimer, 421 N.E.2d 869 (Ill. 1981) | Accrues when plaintiff knows or reasonably should know of injury and its causal connection to defendant's conduct | Active filings reported; Tirrell Allen (Illinois resident) filed November 2024. September 2024 global withdrawal is likely discovery date for most plaintiffs. |
| ⚠Tennessee | 1 year from discovery of injury | Tenn. Code Ann. § 28-3-105; discovery rule per Shadrick v. Coker, 963 S.W.2d 726 (Tenn. 1998) | Accrues when injury is discovered or reasonably should have been discovered; narrow construction—mere suspicion insufficient | Shortest SOL in major filing states. September 2024 withdrawal = hard discovery date. Intake must screen for any earlier symptoms that could trigger earlier accrual. |
| New York | 3 years from discovery | N.Y. C.P.L.R. § 214-c; discovery rule per LaRosa v. Scientific Design Co., 402 N.E.2d 1275 (N.Y. 1980) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, the injury and its cause; 10-year repose cap from act/omission per § 214-c(2) | 2019 FDA approval to 2024 withdrawal falls within repose period. September 2024 withdrawal is clear discovery trigger. |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule per Neagle v. Nelson, 685 S.W.2d 11 (Tex. 1985) | Accrues when plaintiff discovers, or in exercise of reasonable diligence should have discovered, the nature of the injury | Large sickle cell patient population. September 2024 withdrawal is discovery date for most. No MDL means state court filings likely. |
| Georgia | 2 years from discovery | O.C.G.A. § 9-3-33; discovery rule per Am. Medical Int'l, Inc. v. Giurintano, 596 S.E.2d 604 (Ga. 2004) | Accrues when plaintiff discovers, or through reasonable diligence should have discovered, both the injury and its cause; 10-year repose for medical products per § 9-3-71(b) | Significant sickle cell population. 2019 approval to 2024 withdrawal within repose. September 2024 withdrawal = discovery trigger. |
| North Carolina | 3 years from discovery | N.C. Gen. Stat. § 1-52(16); discovery rule per Sawyer v. Foster, 615 S.E.2d 42 (N.C. 2005) | Accrues when plaintiff discovers, or should have discovered through reasonable diligence, the injury and its cause; 10-year repose per § 1-50(a)(5) for products liability | Extended SOL favorable for intake. September 2024 withdrawal is discovery date. Repose period covers 2019-2024 marketing. |
Live intelligence
AI litigation brief
Oxbryta remains active litigation category with 9 current signals in the accepted feed.
Overview
Federal cases coordinated in N.D. Cal. under Judge Trina L. Thompson with three confirmed settlements reached through court-ordered mediation by retired Judge Philip S. Gutierrez. First bellwether trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). No MDL established; litigation proceeding through informal coordination with active settlement momentum.
Key developments
Trajectory
Press and regulatory signals are moving in tandem for Oxbryta. The next escalation check is whether these agency actions prompt new PACER filings or MDL scheduling orders.
Editorial intelligence
Editorial coverage should stay tied to source-backed developments and avoid placeholder status copy for Oxbryta.
Generated Jun 26, 2026, 12:00 AM UTC
9 events detected
Google News (6)
Voxelotor Shows Improved Hemoglobin With Expected Safety in SCD After Removal From Global Markets - Docwire News
EU agency confirms continued suspension of SCD therapy Oxbryta - Sickle Cell Disease News
Sickle Cell Drug Suspension Confirmed by EMA - Medscape
LaRuby May and team of attorneys file suit against Pfizer, claim negligence in premature release of sickle cell drug therapy - AFRO American Newspapers
NAACP and Singleton Schreiber Announce Official Partnership to Pursue Justice for Sickle Cell Patients Harmed by Pfizer’s Oxbryta - NAACP
NAACP and Singleton Schreiber Announce Official Partnership to Pursue Justice for Sickle Cell Patients Harmed by Pfizer’s Oxbryta - NAACP
Journal of managed care & specialty pharmacy • Richards KM • PMID 42341075 • Journal Article.
British journal of haematology • Saraf SL • PMID 42151038 • Journal Article.
No recent court filing signals. Monitoring is active — this section updates automatically.
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
42Score
Fresh items are present but not yet surging
Monitoring
Live
monitoring
Last: Jun 26, 2026, 12:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
9
events detected
AI Brief
Oxbryta remains active litigation category with 9 current signals in the accepted feed.
Overview
Federal cases coordinated in N.D. Cal. under Judge Trina L. Thompson with three confirmed settlements reached through court-ordered mediation by retired Judge Philip S. Gutierrez. First bellwether trials scheduled for June 7, 2027 (Allen) and September 13, 2027 (Ford). No MDL established; litigation proceeding through informal coordination with active settlement momentum.
Key developments
Docwire News news on Feb 26: Voxelotor Shows Improved Hemoglobin With Expected Safety in SCD After Removal From Global Markets - Docwire News. ‖ FAERS FDA alert on Mar 11: FAERS Filing 26483176: Cerebrovascular accident. ‖ PubMed research on Jul 1: Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease..
Generated Jun 26, 2026, 12:00 AM UTC